To date, the expression of PD-L1 on tumor biopsy by immunohistochemistry is the only approved predictive biomarker, although it presents some drawbacks; its expression can vary spatially and over time and can be dependent on the pathologist’s interpretation [9]. Here, CD274 is linked to neoplasm.